Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
DSV, 1107 - MANAGERS’ TRANSACTIONS IN DSV A/S SHARES
-
Lactalis Canada Releases 2023 ESG Report
-
ChainGPT Pad launches Engines of Fury, bringing enhanced Web3 gaming experiences to mainstream players
-
ChainGPT Pad launches Engines of Fury, bringing enhanced Web3 gaming experiences to mainstream players
-
DIII-D National Fusion Facility Completes Upgrade
-
INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in QuidelOrtho Corporation with Losses to Contact the Firm
-
Leading Asian crypto info provider CoinNess launches English Live Feed with free API offer
-
Leading Asian crypto info provider CoinNess launches English Live Feed with free API offer
-
Toll Brothers Announces New Regency Active-Adult 55+ Community Coming Soon to Raleigh, North Carolina
-
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in VinFast Auto Ltd. with Losses to Contact the Firm
-
Children’s Home Society Recruiter Honored By the Dave Thomas Foundation for Adoption
-
Three Life Extension Supplements Finalists for 2024 NutraIngredients Product of the Year Award
-
GLOBAL MINISTRY PULSE EVANGELISM KICKS OFF YEAR-LONG ANTHEM OF GRACE CAMPAIGN AFTER 67 MILLION PEOPLE WATCH ANNUAL GOOD FRIDAY BROADCAST
-
Candor Expedite Unveils Pioneering Technology for the Food Industry
-
Jet.AI Announces the Launch of its National Jet Card Program
-
NP Digital Launches Its New Mail Grader Tool To Audit Email Marketing
-
First Merchants Corporation Announces Retirement of Board Chair Charles E. Schalliol and Appointment of New Board Chair Jean L. Wojtowicz
-
Cultura Technologies Appoints Jeff Schreiner as SVP of Global Collaboration
-
NASDAQ: MBUU INVESTOR ALERT: Berger Montague Advises Malibu Boats (NASDAQ: MBUU) Investors of a June 28, 2024 Deadline
-
Whitsons Culinary Group expands sustainability efforts through Taskforce Green Program
-
Carrie Piltz Appointed to Spearhead Enterprise Partnerships for MissionSquare Retirement
-
Derm-Biome Pharmaceuticals and TransBIOtech awarded $450,000 Applied Research and Development (ARD) grant funding
-
Vaisala Corporation: Managers’ Transactions – Bresky, Annica
-
Vaisala Corporation: Managers’ Transactions – Rosenberg, Lotte
-
Vaisala Corporation: Managers’ Transactions – Jääskeläinen, Antti
-
Vaisala Corporation: Managers’ Transactions – Syrjänen, Tuomas
-
Vaisala Corporation: Managers’ Transactions – Rinnevaara, Jukka
-
Vaisala Corporation: Managers’ Transactions – Ståhlberg, Kaarina
-
Vaisala Corporation: Managers’ Transactions – Castrén, Petri
-
Vaisala Corporation: Managers’ Transactions – Voipio, Raimo
-
Vaisala Corporation: Managers’ Transactions – Voipio, Ville
-
Cutting-Edge Technology Meets Top-Class Sport: AWOL Vision Announces Collaboration with Ilkay Gündoğan
-
UPDATE - iCAD to Report First Quarter 2024 Financial Results on May 15, 2024
-
USOSM’s Henry Moomaw Recognized as ‘Outstanding CFO: Large Private Company’
-
Form 8.3 - UK Commercial Property REIT Limited
-
Form 8.3 - Tritax Big Box Reit Plc
-
Form 8.3 - Mattioli Woods
-
Shape Therapeutics RNAfix® Editing Platform Achieves >90% Editing in Mouse and Non-Human Primate Brain
-
Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board
-
Shape Therapeutics RNAfix® Editing Platform Achieves >90% Editing in Mouse and Non-Human Primate Brain
-
Form 8.3 - Lok’n Store Group PLC
-
CN is Presenting 2023 Safe Handling Award to 193 Rail Shippers
-
CAULIPOWER, The Better-For-You Brand Reinventing America’s Favorite Comfort Foods, Announces Veteran CPG Executive Tyler Ricks as New CEO
-
Phone.com Unveils New Conversational AI Service: AI-Connect
-
Form 8.3 - GCP Asset Backed Income Fund Limited
-
Vector Institute announces nearly $2 million in scholarships for top Ontario AI graduate students
-
Form 8.3 - Balanced Commercial Property Trust Limited
-
Invesco Ltd: Form 8.3 - Virgin Money UK PLC
-
LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”
-
FDA Grants Orphan Drug Designation to Biompharma’s Bi104, a microbiome-modifying biologic, for the treatment of Angelman Syndrome
